Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to respond

UTILITY
PATENT APPLICATION
TRANSMITTAL

09

and to respond to a sense and the sense	THE CONTROL OF THE PROPERTY OF THE CONTROL HUMBER
Attorney Docket No.	GR2351US5
First Inventor	Michael Thomas RIEBE
Title	MEDICAMENTS
Express Mail Label	EV330915601US

(Only for new nonprov	risional applications under	37 CFR 1.53(b))	Express I	Mail Label		EV3	330915601US	
	PPLICATION ELEN 600 concerning utility pai		contents.	A	ADDRESS T	O. Commiss P. O. Box	Patent Application sioner for Patents (1450 ia VA 22313-1450	
2. (Submit ar. Applicant See 37 C 3. Specifica (preferred - Descrip - Cross F - Stateme - Referen or a con - Backgro - Brief St - Brief De - Detailed	arrangement set forth be- tive title of the inventi- Reference to Related A ent Regarding Fed sp- ice to sequence listing inputer program listing bund of the Invention armary of the Invention escription of the Drawid I Description	tor fee processing tatus. Total Pages low) on Applications onsored R & E g, a table, a appendix	18]	(if appli a. b. c.	Computer Fotide and/or a cable, all nece Specification i	r CD-R in dup Program (App Amino Acid S issary) puter Readal on Sequence CD-ROM or G Paper ements verify	plicate, large table o pendix) Sequence Submission ple Form (CRF)	si 10/694163
	t of the Disclosure	Total Sheets	2]	11.	(when there is	slation Docu	Power of properties of the pro	•
b. J i. [Newly executed (origi Copy from a prior app (for continuation/divisional DELETION OF Signed statemen named in the prio 1.63(d)(2) and 1. on Data Sheet. See 3	dication (37 CF al with Box 18 co FINVENTOR(statached deletion or application, se 33(b).	mpleted) S) ng inventor(s) e 37 CFR	13.	Preliminary A Return Rece (Should be sp Certified Co (if foreign prior Nonpublicati (b)(2)(B)(i). or its equiva	ecifically itemiz py of Priority rity is claimed) ion Request Applicant mu lent.	(MPEP 503) red) Document(s) under 35 U.S.C. 122 ust attach form PTO	2
pecification following to Continuat Prior application For CONTINUATION LUNDAR BOY 50		Continu Continu inner HAGHIC only: The enti	nder 37 CFR ation-in-par GHATIAN re disclosur e accompan	t (CIP) of proper of the prior	ior application Group application, for or division	on No.: o / Art Unit: 10 rom which are	10/185,193 616 n oath or declaration	norated
		19. CO	RRESPO	NDENCE AD	DRESS			
Custo	omer Number:		2334	7	o	r 🗀 Coπ	espondence address be	elow
Name	t J. Smith							
Glaxo	SmithKline							
Address	Moore Drive							
	* -		State	NC		Zip Code	27709	
City Resea	rch Triangle Park						 	
a , l								
Country US		Те	lephone	919-483-9616		Fax	919-483-7988	_
	Robert J. Smith	Te	iepnone		tration No. (40,820	$\overline{}$

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSM	IITTAL	Complete if Known				
		Application Number				
l for FY 20	03	Filing Date				
Effective 01/01/2003. Patent fees are subject	ct to annual revision.	First Named Inventor	Michael Thomas RIEBE			
Applicant claims small entity status. See 37 CFR 1.27		Examiner Name	HAGHIGHATIAN			
		Art Unit	1616			
TOTAL AMOUNT OF PAYMENT (\$) \$750.00		Attorney Docket No.	GR2351US5			
METHOD OF PAYMENT (chec	ck all that apply)	FEE CA	ALCULATION (continued)			
Check Credit card Mone Oth	er None 3.	ADDITIONAL FEES				

MF	METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)											
Check	Credit			Other None		DDITIC	ONAL I		;			
Deposit A	Account:			!	Fee	Fee	Fee	Fee	_	Descriptio	on	Fee Paid
Deposit Account	<i></i>		07-1392	2	1051	(\$) 130	2051		Surcharge - late	•		
Number L Deposit F		=			1052	50	2052	25		provisional	filing fee or cover	
Account Name	i _	(GlaxoSmith	Kline	1053	130	1053	130	sheet Non - English sp	pecification		
The Director is	s authoriz	ed to	: (check all t	that apply)		2,520			- ,	•	arte reexamination	
I.—.	e(s) indicate			dit any overpayments	1804	920*	1804	920*	Requesting publ	lication of SI	IR prior to Examiner	
Charge any	y additona'	ıl fee(s	i) during the pende	ency of this application	1805	1,840*	1805	1,840*	Requesting publ	lication of S	IR after Examiner	
			low, except for the	e filing fee	1251	110	2251	55	action Extension for rep	olv within fir	et month	
to the above-ide					1251		1		Extension for rep			
1 PACK			ALCULATIO	אַל	1253		1		Extension for rep	• •		
1. BASIC				!		1,450	1	725	Extension for rep	ply within fo	urth month	
Fee Fee	e Fee F	Fee		on Fee Paid	1255	1,970	2255	985	Extension for rep	ply within fif	th month	
Code (\$) 1001 750	·		Utility filing fee		1401	320	2401	160	Notice of Appeal	ıl .		
1002 330			Design filing		1402	320	2402	160	Filing a brief in s	support of ar	ı appeal	
1003 520			Plant filing fee		1403	280	2403	140	Request for oral	hearing		
1004 750	2004 3		Reissue filing		1451	1,510	1451	•	Petition to institu	•	•	
1005 160	2005	80	Provisional filin	ıg fee	1452	110	1		Petition to revive			
	'	SU	BTOTAL (1)	(\$) \$750.00	1453	1,300	1		Petition to revive			
2 FXTR/	4 CLAII	M FE	ES FOR UTIL	ITY AND		1,300			Utility issue fee (
4. 4				Fee from	1502				Design issue fee	3		
Total Claims		tra Cl -20**		below Fee Paid	1503				Plant issue fee			
Independent		- 3**		= 0.00	1460		1		Petitions to the C			
Claims Multiple Depe	endent		Ī	=	1807		1		Processing fee u		•	
Large Entity					1806	180	1806		Submission of In Statement			
Fee Fee Code (\$)		Fee (\$)	Fee Des	cription	8021	40	8021	40	Recording each (times number o	patent assign of properties	gnment per property	
1202 18		9	Claims in exce		1809	750	2809	375	Filing a submiss	sion after fina	•	
1201 84	.		•	claims in excess of 3	1810	750	2810	375		onal invention	on to be examined	
1203 280			, ,	ndent claim, if not paid	1801	750	2801	375	(37 CFR § 1.12 Request for Con		mination (RCF)	<u></u>
1204 84	2204 4	42	over original	ependent claims patent	1801				Request for exp		` '	
1205 18	2205	9	** Reissue clair and over orig	ims in excess of 20 ginal patent			(specify)	•	of a design appli		THE MAN TO SERVICE AND THE SER	
	- (SUB	STOTAL (2)	(\$) \$0.00				_				
**or number	previoust	y paic	d, if greater; For	Reissues, see above	*Rer	duced t	y Basic	: Filing	Fee Paid	SUBTOT	TAL (3) (\$)	
SUBMITTE	ED BY									Complete (ii	if applicable)	
Name			Rober	rt J. Smith		Registra (Attorney	ration No y/Agent)		40,820	Telephone	919-483-9	<i>)</i> 616

SUBMITTED BY	<u> </u>			Complete (i		
Name	Robert J. Smith	Registration No. (Attorney/Agent)	40,820	Telephone	919-483-9616	
Signature	West flut			Date	10-27-03	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	MAIL" (37 CFR 1.10)	Docket No.	
Applicant(s): RIEBE, et		GR2351US5	
Serial No.	Filing Date	Examiner	Group Art Unit
Invention:	· · · · · · · · · · · · · · · · · · ·		
MEDICAMENTS			
I hereby certify that thi	s <u>Utility Patent Application</u>		
		(Identify type of correspondence)	
is being deposited wit	h the United States Postal Servi	ce "Express Mail Post Office to A	ddressee" service under
37 CFR 1.10 in an env	velope addressed to: Director of	the United States Patent and Tra-	demark Office, P.O. Box
. 1450, Alexandria, VA	22313-1450 on	10 21 03	
		(9	
		Ban Younan	
		(Typed or Printed Name of Person Mai	ling Correspondence)
		(Signature of Person Milling Co	ntresnandence)
		EV330915	
		("Express Mail" Mailing Lat	
	Note: Each paper must ha	eve its own certificate of mailing.	